Is it appropriate to switch from enoxaparin to rivaroxaban for deep‑vein thrombosis prophylaxis while the patient is hospitalized?

Switching from Enoxaparin to Rivaroxaban for DVT Prophylaxis in Hospitalized Patients

For hospitalized medical patients requiring DVT prophylaxis, you should continue enoxaparin throughout the hospital stay rather than switching to rivaroxaban. The most recent high-quality guidelines explicitly recommend against using rivaroxaban for VTE prophylaxis in acutely ill hospitalized medical patients due to increased bleeding risk without clear benefit 1.

Evidence-Based Rationale

Why Enoxaparin Should Be Continued

The 2018 ASH guidelines make a strong recommendation for using LMWH (like enoxaparin) only during hospitalization, rather than switching to or using DOACs like rivaroxaban 1. This is based on moderate-certainty evidence showing:

• Rivaroxaban increases bleeding risk in hospitalized medical patients without providing superior VTE prevention
• The MAGELLAN trial demonstrated rivaroxaban was associated with more bleeding events compared to standard enoxaparin prophylaxis 2, 3
• While rivaroxaban showed non-inferiority for VTE prevention, the bleeding complications outweighed any potential benefits in the inpatient setting

Current Guideline Recommendations

For hospitalized medical patients, the standard approach is 4, 2:

• Enoxaparin 40 mg subcutaneously once daily throughout hospitalization
• Continue until the patient is fully ambulatory or discharged
• Alternative options include UFH 5,000 units every 8 hours or fondaparinux 2.5 mg once daily

When Rivaroxaban May Be Appropriate

Rivaroxaban (10 mg once daily) can be considered only in specific contexts 5:

1. Ambulatory cancer patients receiving systemic therapy with intermediate-to-high VTE risk (Khorana score ≥2) and low bleeding risk
2. Post-discharge extended prophylaxis in select high-risk patients after completing inpatient enoxaparin
3. Orthopedic surgery patients (hip/knee replacement) - where rivaroxaban 10 mg daily has proven efficacy 2, 3

Critical Pitfalls to Avoid

• Do not switch anticoagulants mid-hospitalization without compelling clinical indication - this increases bleeding risk and provides no proven benefit 4
• Avoid rivaroxaban in patients with severe renal impairment (CrCl <30 mL/min) - it is contraindicated 2, 3
• Do not use rivaroxaban for routine inpatient medical prophylaxis - guidelines from 2013-2018 consistently recommend against this practice 6, 1

Practical Algorithm

If patient is hospitalized and on enoxaparin for DVT prophylaxis:

1. Continue enoxaparin 40 mg SC daily until discharge or full ambulation
2. At discharge, reassess VTE risk:
   • If low risk: discontinue prophylaxis
   • If high risk (active cancer, recent VTE, prolonged immobility expected): consider extended prophylaxis with rivaroxaban 10 mg daily OR continue enoxaparin
3. For cancer patients specifically: LMWH remains preferred, but rivaroxaban 10 mg daily is an acceptable alternative for ambulatory patients with low bleeding risk 5

Special Considerations

The 2022 ITAC guidelines note that while rivaroxaban can be used for outpatient VTE prophylaxis in select cancer patients, the evidence for switching during hospitalization remains insufficient 5. The switch-therapy approach (enoxaparin inpatient → rivaroxaban outpatient) has been studied primarily in orthopedic surgery settings 7, 8, 9, not general medical patients.

Bottom line: Keep hospitalized medical patients on enoxaparin for DVT prophylaxis. Reserve rivaroxaban for post-discharge extended prophylaxis in carefully selected high-risk patients, or for specific approved indications like orthopedic surgery prophylaxis.